- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Wagner presents results on ADAC's MCD
At last month's European Association of Nuclear Medicine Congress in Glasgow, Scotland, Dr. Henry Wagner presented preliminary results on the Molecular Coincidence Detection high-energy imaging technique under development by ADAC Laboratories of
At last month's European Association of Nuclear Medicine Congress in Glasgow, Scotland, Dr. Henry Wagner presented preliminary results on the Molecular Coincidence Detection high-energy imaging technique under development by ADAC Laboratories of Milpitas, CA. Wagner, who is a professor of radiation health sciences at John Hopkins Medical Institutions in Baltimore, said MCD could change the way patients with lung cancer are treated.
Wagner is participating in a multicenter clinical trial sponsored by ADAC to demonstrate the clinical effectiveness of MCD in oncology patients whose cancer may have metastasized. ADAC hopes that MCD can help differentiate between benign and malignant nodules, and determine whether surgical treatment is most appropriate.
In Wagner's trials, 35 patients were studied, with MCD producing a 96% sensitivity and an 80% specificity. Results from MCD could enable physicians to identify, prior to surgery, lung cancer patients who have a good chance of surgical cure and those who should be treated instead by radiation or chemotherapy, thus avoiding unnecessary surgery, according to Wagner.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
